Positioning biologics and new therapies in the management of inflammatory bowel disease

被引：6

作者：

Honap, Sailish ^{[1
]}

Cunningham, Georgina ^{[1
]}

Tamilarasan, Aravind Gokul ^{[1
]}

Irving, Peter M. ^{[1
]}

机构：

[1] Guys & St Thomas Hosp NHS Fdn Trust, IBD Ctr, London, England

来源：

CURRENT OPINION IN GASTROENTEROLOGY | 2019年 / 35卷 / 04期

关键词：

biologic; inflammatory bowel disease; positioning; small molecules; CROHNS-DISEASE; MAINTENANCE THERAPY; COMBINATION THERAPY; INDUCTION; VEDOLIZUMAB; USTEKINUMAB; INFLIXIMAB; CONSENSUS; IMMUNOGENICITY; AZATHIOPRINE;

D O I：

10.1097/MOG.0000000000000546

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Purpose of review Since the advent of anti-tumour necrosis factor agents, knowledge of their optimal use and their pitfalls has grown exponentially. However, the range of therapeutic agents available to clinicians and patients is expanding, creating challenging decisions about which drugs to use at any given time point. The present review aims to provide a framework within which positioning decisions can be made in the context of limited comparative effectiveness data. Recent findings The present review will summarize the current literature emphasizing how best to use biologic agents, and will provide suggestions as to how they should be positioned. Recent trials comparing efficacy and safety will be considered as will their strengths and weaknesses. Summary On reading this review, clinicians should have an understanding of the optimal use of currently approved biologic agents and tofacitinib and how they might be positioned in relation to one another.

引用

页码：296 / 301

页数：6

共 33 条

[1] One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study [J].

Amiot, A. ;

Serrero, M. ;

Peyrin-Biroulet, L. ;

Filippi, J. ;

Pariente, B. ;

Roblin, X. ;

Buisson, A. ;

Stefanescu, C. ;

Trang-Poisson, C. ;

Altwegg, R. ;

Marteau, P. ;

Vaysse, T. ;

Bourrier, A. ;

Nancey, S. ;

Laharie, D. ;

Allez, M. ;

Savoye, G. ;

Moreau, J. ;

Vuitton, L. ;

Viennot, S. ;

Aubourg, A. ;

Pelletier, A. -L. ;

Bouguen, G. ;

Abitbol, V. ;

Gagniere, C. ;

Bouhnik, Y. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (03) :310-321

[2]

Bohm M, 2018, COMMUNICATION FEB

[3] Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].

Colombel, Jean Frederic ;

Sandborn, William J. ;

Reinisch, Walter ;

Mantzaris, Gerassimos J. ;

Kornbluth, Asher ;

Rachmilewitz, Daniel ;

Lichtiger, Simon ;

D'Haens, Geert ;

Diamond, Robert H. ;

Broussard, Delma L. ;

Tang, Kezhen L. ;

van der Woude, C. Janneke ;

Rutgeerts, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395

[4] The safety of vedolizumab for ulcerative colitis and Crohn's disease [J].

Colombel, Jean-Frederic ;

Sands, Bruce E. ;

Rutgeerts, Paul ;

Sandborn, William ;

Danese, Silvio ;

D'Haens, Geert ;

Panaccione, Remo ;

Loftus, Edward V., Jr. ;

Sankoh, Serap ;

Fox, Irving ;

Parikh, Asit ;

Milch, Catherine ;

Abhyankar, Brihad ;

Feagan, Brian G. .

GUT, 2017, 66 (05) :839-851

[5] Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease [J].

D'Haens, Geert ;

Vermeire, Severine ;

Lambrecht, Guy ;

Baert, Filip ;

Bossuyt, Peter ;

Pariente, Benjamin ;

Buisson, Anthony ;

Bouhnik, Yoram ;

Filippi, Jerome ;

Vander Woude, Janneke ;

Van Hootegem, Philippe ;

Moreau, Jacques ;

Louis, Edouard ;

Franchimont, Denis ;

De Vos, Martine ;

Mana, Fazia ;

Peyrin-Biroulet, Laurent ;

Brixi, Hedia ;

Allez, Matthieu ;

Caenepeel, Philip ;

Aubourg, Alexandre ;

Oldenburg, Bas ;

Pierik, Marieke ;

Gils, Ann ;

Chevret, Sylvie ;

Laharie, David .

GASTROENTEROLOGY, 2018, 154 (05) :1343-+

[6] Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice [J].

Danese, Silvio ;

Bonovas, Stefanos ;

Peyrin-Biroulet, Laurent .

JOURNAL OF CROHNS & COLITIS, 2017, 11 (10) :1258-1266

[7] The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium [J].

Dulai, Parambir S. ;

Singh, Siddharth ;

Jiang, Xiaoqian ;

Peerani, Farhad ;

Narula, Neeraj ;

Chaudrey, Khadija ;

Whitehead, Diana ;

Hudesman, David ;

Lukin, Dana ;

Swaminath, Arun ;

Shmidt, Eugenia ;

Wang, Shuang ;

Boland, Brigid S. ;

Chang, John T. ;

Kane, Sunanda ;

Siegel, Corey A. ;

Loftus, Edward V. ;

Sandborn, William J. ;

Sands, Bruce E. ;

Colombel, Jean-Frederic .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (08) :1147-1155

[8]

Falek D, 2018, COMMUNICATION FEB

[9] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease [J].

Feagan, B. G. ;

Sandborn, W. J. ;

Gasink, C. ;

Jacobstein, D. ;

Lang, Y. ;

Friedman, J. R. ;

Blank, M. A. ;

Johanns, J. ;

Gao, L. -L. ;

Miao, Y. ;

Adedokun, O. J. ;

Sands, B. E. ;

Hanauer, S. B. ;

Vermeire, S. ;

Targan, S. ;

Ghosh, S. ;

de Villiers, W. J. ;

Colombel, J. -F. ;

Tulassay, Z. ;

Seidler, U. ;

Salzberg, B. A. ;

Desreumaux, P. ;

Lee, S. D. ;

Loftus, E. V., Jr. ;

Dieleman, L. A. ;

Katz, S. ;

Rutgeerts, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1946-1960

[10] Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis [J].

Feagan, Brian G. ;

Rutgeerts, Paul ;

Sands, Bruce E. ;

Hanauer, Stephen ;

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Van Assche, Gert ;

Axler, Jeffrey ;

Kim, Hyo-Jong ;

Danese, Silvio ;

Fox, Irving ;

Milch, Catherine ;

Sankoh, Serap ;

Wyant, Tim ;

Xu, Jing ;

Parikh, Asit .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :699-710

← 1 2 3 4 →